Muscle structure and stiffness assessment after botulinum toxin type A injection. A systematic review  by Mathevon, L. et al.
Annals of Physical and Rehabilitation Medicine 58 (2015) 343–350Literature review
Muscle structure and stiffness assessment after botulinum toxin type
A injection. A systematic review
L. Mathevon a,*, F. Michel b, P. Decavel b, B. Fernandez a, B. Parratte c, P. Calmels a
a Service de me´decine physique et de re´adaptation, laboratoire de physiologie de l’exercice, universite´ Jean-Monnet, CHU de Saint-E´tienne, Saint-E´tienne,
France
b Service de me´decine physique et de re´adaptation, universite´ de Franche-Comte´, CHU de Besanc¸on, Besanc¸on, France
c Service de me´decine physique et de re´adaptation, laboratoire d’anatomie, universite´ de Franche-Comte´, CHU de Besanc¸on, Besanc¸on, France
A R T I C L E I N F O
Article history:
Received 17 June 2014
Accepted 11 June 2015
Keywords:
Spastic muscle
Botulinum toxin
Atrophy
Stiffness
Literature review
A B S T R A C T
Background: Botulinum toxin type A manages spasticity disorders in neurological central diseases. Some
studies have reported that it might induce muscle changes.
Methods: We present a literature review abiding by the PRISMA statement guidelines. The purpose was
to explore the structural and passive biomechanical muscle properties after botulinum toxin type A
injections in healthy and spastic limb muscles, on animals and humans, as well as methods for evaluating
these properties. We searched the PubMed and Cochrane Library databases using the following
keywords: ‘‘Botulinum toxin’’ AND (‘‘muscle structure’’ OR ‘‘muscle atrophy’’) and, ‘‘Botulinum toxin’’
AND ‘‘muscle elasticity’’.
Results: From the 228 initially identiﬁed articles, 21 articles were included. Histological analyses were
performed, especially on animals. A neurogenic atrophy systematically occurred. In humans, one year
after a single injection, the histological recovery remained incomplete. Furthermore, 2D ultrasound
analyses showed a reduction of the gastrocnemius thickness and pennation angle. MRI volumetric
analysis evidenced muscular atrophy six months or one year after a single injection. Passive muscle
stiffness depends on these structural changes. On the short term, the biomechanical analysis showed an
elastic modulus increase in animals whereas no change was recorded in humans. On the short term,
ultrasound elastography imaging showed a decreased elastic modulus.
Discussion: To date, few data are available, but all show a structural and mechanical muscle impact post
injections, speciﬁcally muscle atrophy which can linger over time. Further studies are necessary to
validate this element, and the possibility of change must be taken into account particularly with
repeated injections. Thus, in clinical practice, 2D ultrasound and ultrasound elastography are two non-
invasive techniques that will help physicians to develop an efﬁcient long term monitoring.
 2015 Elsevier Masson SAS. All rights reserved.
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The spastic paretic muscle is subject to structural changes
compared to healthy skeletal muscles. These changes are indepen-
dent from the initial etiology of the neurological lesion. The
literature describes an increased variability of the size and type of
muscle ﬁbers, decreased numbers of sarcomeres, proliferation of the
extracellular matrix (ECM) with an increased collagen concentration
[1,2]. When the ﬁrst motor neuron is affected, muscle retraction can
get settled under the inﬂuence of two main factors. The disuse of the* Corresponding author. Tel.: +33 6 89 53 16 63; fax: +33 4 77 12 77 72.
E-mail address: Laure.mathevon@laposte.net (L. Mathevon).
http://dx.doi.org/10.1016/j.rehab.2015.06.002
1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.paretic muscle or ‘‘functional immobilization’’, which initiates
muscle atrophy and reduces the number of sarcomeres by a
disequilibrium of the protein-proteolysis synthesis balance in favor
of the proteolysis [3,4]. Chronic muscle hyperactivity maintains the
muscle in a short position, reducing the longitudinal tension
[5]. Thus, the shortening of the muscle ﬁbers and accumulation of
conjunctive tissue are responsible of these changes in biomechanical
viscoelastic properties of the muscles, with a decreased passive
extension capacity [3–6].
Muscle changes contribute to functional impairments. Gait
speed and step length have been signiﬁcantly correlated to passive
mechanical properties of the plantar ﬂexor muscles, determined by
the measure of the passive torque/joint angle ratio of the talocrural
joint [7]. For Dietz and Sinkjaer, the spastic muscle at rest is
Table 1
Quality analysis form used in the systematic review.
Q1 Is there in the abstract an explanation of what was done and
found?
Q2 Is the scientiﬁc context clearly explained?
Q3 Are the objectives clearly stated?
Q4 Is the sampling size indicated?
Q5 If yes, is the sampling size statistically justiﬁed?
Q6 Are the characteristics of the subjects (height, weight, sex, healthy
or pathologic subject) described?
Q7 What is the design of the study? (0: retrospective study; 1: case
study; 2: prospective study).
Q8 Is there a control group? (0: no, 1: contralateral member or non-
randomized control group, 2: randomized control group).
Q9 How long is the follow up? (0:  1month; 1  6 month; 2  1 year)
Q10 Is the reliability of the evaluation method clearly described?
Q11 Are the results interpretable?
Q12 Are the limitations of the study discussed?
Q13 Is the conclusion clearly stated?
0: no description; 1: limited description; 2: good description.
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(presynaptic inhibition and increased activity of type Ia ascending
ﬁbers) with little changes during voluntary contractions. Thus,
hyperreﬂexia is hardly involved in pathologic spastic movements
[6].
Injections of botulinum toxin type A (BoNtA) are a ﬁrst-line
therapeutic method to treat focal spasticity [8]). Their action is
triggered by the ﬁxation on the SNARE proteins and inhibited
release of acetylcholine (ACh) from the presynaptic terminals. The
therapeutic objective is to decrease reﬂex muscle overactivity and
ﬁght muscle hypertonia. The functional beneﬁt will affect gait
patterns and movement amplitude [9–12]. However, the impact
of BoNtA injections on muscle structure and the stretching
capacity of muscle tissue have rarely been reported in the
literature. The challenge is to differentiate the consequences
related to spastic paresis from those linked to the injections of
botulinum toxin. We propose a review of the literature with the
following objectives:
 analyze changes in the structure and stiffness of muscle tissue
described after an injection of botulinum toxin in one muscle of
the limbs;
 discuss the evaluation methods used.
2. Methodology
A systematic review of the literature was conducted abiding by
the PRISMA recommendations (www.prisma-statement.org). We
searched the Pubmed and Cochrane Library databases, using the
following keywords
‘‘Botulinum toxin’’ AND (‘‘muscle structure’’ OR ‘‘muscle
atrophy’’) and, ‘‘Botulinum toxin’’ AND ‘‘muscle elasticity’’. Articles
stemming from this research were independently put aside by
2 authors (LM and BP) and were then evaluated. Articles were kept
if they met the following criteria:
 the study focused on the analysis of a striated skeletal muscle of
the limbs, paretic spastic or healthy (to differentiate changes
related to spastic paresis), in men and humans;
 the study analyzed the consequences of injections of botulinum
toxin on muscle structure and/or muscle tissue stiffness;
 evaluation methods in the ﬁelds of histological, mechanical and
medical imaging analyses were described;
 the full manuscripts were published in English between
1990 and October 2014. References of the articles included
were used to eventually complete the selection. In case of
disagreement, a decision was taken after further discussion.
The methodological quality of the articles was evaluated using a
speciﬁc scale developed based on the STROBE (Strengthening the
Reporting of Observational studies in Epidemiology) principles
[13]. Each item was categorized, and the maximum global score is
28 (Table 1).
3. Results
3.1. Selection of the studies
In all, 228 articles were initially identiﬁed (Fig. 1). Thirty-two
articles were deemed relevant after reading the titles and
abstracts. Twenty-one were included in the review (11 were
excluded because they did not meet the selection criteria).
Fourteen studies focused on the structural analysis, 3 studies on
muscle stiffness analysis and 4 studies on both structure and
stiffness analysis. Overall, there were very few studies, with often arestricted population sample (from 1 to 56 patients in men) and
various exploration methods.
3.2. Quality of the reviewed articles
The quality of the reviewed articles is summed up in Table 2. It
is highly variable. Most studies were prospective ones, except for
2 case studies [14,15] and a retrospective study [16]. The
descriptive quality of the experimental protocol, results as well
as their interpretation and conclusion was adequate in most
studies. The reproducibility of evaluation method was rarely
described. No study proposed sample size calculations. The follow-
up duration was quite short in most studies ( 3 months).
3.3. Literature analysis (Table 3)
The methodological variability among the small number of
studies, made it mandatory to conduct an evaluation based on
changes in muscle structure and passive mechanical properties
and according to the exploration techniques used.
3.3.1. Structural changes
Analysis via muscle samples in animals, muscle mass analysis
based on post-mortem dissection reports post-injection atrophy
[17–24]. It occurs from 1 week [22,24] to 4 months [24] after one
injection, with a dose effect. A dose twice as important (6 U Botox/
kg versus 3 U Botox/kg) reduces the delay of onset to one week
(versus 4) [23]. After one single injection, the intensity of the loss in
muscle mass varied from 30 to 60% (dose effects, muscles and
animal injected) according to the various studies [17–24]. The
recovery was highlighted at 4 months [23] or 1 year [24]. The
recovery was incomplete, in the range of 90% recovery of the initial
muscle mass. Following repeated monthly injections, Fortuna et al.
[19] brought up the possibility of a ceiling effect of the atrophy
after the third injection, around 60%. At one year, results showed
that repeating an injection at 6 months majors muscle atrophy and
in a dose-dependent manner.
Histological slides were used to analyze muscle ﬁbers [17–19,
21,22,24,25], via optical (OM) [17] and electronic microscopy (EM)
[22,24]. A precise analysis of contractile proteins [19,21] (auto-
mated measurement technique: Mat Lab Program) [19] was
conducted which also included the composition of myosin heavy
chains, titin molecular mass (gel electrophoresis), extracellular
matrix and amount of collagen (hydroxyproline assay) [25]. After
one single injection, the structure of the sarcomeres is altered with
a misalignment of Z-lines. The initial structure was restituted at
6 months [24]. Changes in contractile proteins were observed.
Fig. 1. Selection diagram of the reviewed articles. * A common study in humans and animals. Some articles are referring to multiple methods and ﬁelds of investigation.
Table 2
Quality assessment.
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Total (max = 28)
Alhusaini et al. (2011) 2 2 1 2 2 2 2 0 1 1 2 2 2 21
Boyaci et al. (2014) 2 2 1 2 0 2 2 1 0 0 0 2 1 15
Choi et al. (2007) 2 1 1 2 0 2 2 1 0 1 1 0 2 15
Dodd et al. (2005) 2 2 2 0 0 1 2 2 1 1 1 0 2 16
Fortuna et al. (2011) 2 2 2 2 0 2 2 2 1 1 1 1 2 20
Frick et al. (2007) 2 2 1 2 0 2 2 2 1 1 2 1 2 20
Haubruck et al. (2012) 2 2 2 2 0 2 2 2 0 1 2 2 2 21
Kwon et al. (2012) 1 1 1 2 0 2 1 0 0 0 1 0 2 11
Legerlotz et al. (2009) 2 2 2 2 0 2 2 2 0 1 2 0 2 19
Ma et al. (2004) 2 2 2 2 0 2 2 2 2 2 2 1 2 23
Park and Kwon (2012) 2 2 1 2 0 2 2 0 0 1 1 2 2 17
Picelli et al. (2012) 2 2 2 2 1 1 2 0 0 1 1 2 2 18
Schroeder et al. (2009) 2 2 2 2 0 1 2 1 2 1 2 0 2 19
Shaikh et al. (2014) 1 2 2 2 0 2 0 2 1 1 1 1 2 17
Stone et al. (2011) 2 2 1 2 0 1 2 0 1 1 1 1 2 16
Thacker et al. (2012) 2 2 1 2 0 2 2 1 0 1 2 1 2 18
Tok et al. (2011) 2 1 2 2 0 2 2 0 1 0 1 1 2 16
Tsai et al. (2010) 2 2 1 2 0 1 2 1 2 1 1 1 2 18
Van Campenhout et al. (2013) 2 2 2 2 0 1 2 0 1 2 2 2 1 19
Vasilescu et al. (2010) 1 2 1 2 0 2 1 0 0 0 1 0 1 11
William et al. (2013) 2 2 1 2 0 2 0 0 1 2 2 2 2 18
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Table 3 (Continued )
Author Year Human/
Animal
Control
group
Age Population
(number)
Neurological
Condition
Muscle
system
BoNtA Number
of injections
and dose
Measurement
tool
Study criteria Changes First–Last
evaluation
First
changes
Recovery
OM Muscle structure Neurogenic atrophy
Reinnervation
EM Muscle ultrastucture
Shaikh et al.,
2014
Human Yes Avg:
47 years
(min:
26–max: 63)
12 Piriformis
syndrome
Piriformis Botox, inconstant
injections number,
100 U
MRI Maximal muscle
thickness
Decrease Inconstant
Avg:
7,35,2
months
post-injection
? No
Muscle volume Decrease
Fatty inﬁltration Increase
Stone et al.,
2011
Mouse No ? 140 Healthy GM, GL Botox, 1, inconstant
doses and volumes
Balance Muscle mass Dose- and volume-
dependant decrease
4 weeks–
12 weeks
4 weeks 12 weeks
Thacker et al.,
2012
Rat Contralateral
limb
Mature 24 Healthy TA Botox, 1, 6 U/kg Dynamometer +
Length measure
(muscle ﬁbers)
Elastic modulus Increase 1 month–1
month
1 month ?
Histology Collagen content Increase
Tok et al., 2011 Human Contralateral
limb
Avg: 5514
years
26 Stroke GM, GL ?, 1, ? B-mode US Pennation angle Decrease 10 days–2
months
2 months ?
Fascicular lenght Increase
Muscle thickness Decrease
Muscle
compressibility
None
Tsai et al., 2010 Human No ? 5 Calf
asymetry
TS Botox, 1, 20 ng calf Meter Maximal calf
circumference
Decrease 4 weeks–26
weeks
4 weeks 26 weeks
Rat Yes ? 5 Healthy GCM 3 groups: 1,5 ng/kg
6 months repeated 1,5
ng/kg 6 months
repeated 1 ng/kg
EM Muscle ultrastucture Sarcomere distorsion 1 week–52
weeks
1 week 26 weeks
Balance Muscle mass Decrease
Van
Campenhout
et al., 2012
Human No Avg: 12 years 7 CP Proximal
psoas Distal
psoas
Botox, 1, 2 U/kg/psoas MRI Muscle volume Decerase (proximal
injected psoas) None
(distal injected psoas)
2 months–
6 months
2 months No
Vasilescu et al.,
2010
Human Contralateral
limb
3–10 years 7 CP Inconstant ? B-mode US Muscle echogenicity
Aponevrosis
echogenicity,
Diame`tre musculaire
No description ? ? ?
Sonoelastography Elasticity pattern with
color map
Softer muscles
William et al.,
2013
Human No 5–11 years 15 CP GCM, So Botox, 1, inconstant
doses
MRI Muscle volume Decrease in injected
muscles
Increase in soleus
muscle
5 weeks 5 weeks ?
Avg: average; CP: cerebral palsy; TS: triceps surae; TA: tibialis anterior; TCJ: talocrural joint; GM: gastromedialis; GL: gastrolateralis; GCM: gastrocnemius muscle; So: soleus; RF: rectus femoris; VS: vastus lateralis; VM: vastus
medialis; US: ultrasonography; EM: electron microscopy; OM: optical microscopy; MHC: myosin heavy chains; NMJ: neuromuscular junction.
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decreases in favor of intermediate Type IIa ﬁbers and slow twitch
Type I ﬁbers, in the gastrocnemius muscles [18,21] and the tibialis
anterior muscle [25]. In monthly injections, the quantity of myosin
heavy chains (MHC) decreases after the 3rd month (in the range of
70% of surface MHC on the rectus femorus and vastus lateralis,
vs. > 90% before the injection as evidenced on histological slides)
[19]. It decreases again down to about 40% at 6 months, on the
vastus lateralis [19]. Finally, 1 month after one injection, the
amount of collagen in the muscle increases (in the order of 40%), as
well as the expression of the titin protein, the most abundant
elastic protein in the muscle ﬁber [21,25].
In humans, only the work of Schroeder et al. [26] reported
histological data based on muscle biopsies. One year after one
single injection of 75 U Xeomin in the lateral gastrocnemius
muscle, the authors reported changes in the muscle structure
[26]. In optical microscopy, the surface of muscle ﬁbers is reduced
by 24%, muscle ﬁbers have an angular shape [27], and the atrophy
is compensated by a process of ﬁbrosis. Under electronic
microscopy, authors evidenced a negative progression of neuro-
muscular junctions, with an increase of the space located between
nerve endings and motor plates. A decrease in the number of crests
of the synaptic folds, where RnAch accumulates, was noted.
3.3.2. Medical imaging analysis
2D ultrasound was used in 4 studies [15,28–30], 2 in children
with cerebral palsy [15,28] and 2 in post-stroke hemiplegic patients
[29,30]. This technique allows a reproducible evaluation of the
muscle by measuring muscle thickness, a section of muscle surface
and the pennation angle [21]. Tok et al. [30] and Picelli et al. [29]
respectively reported results on 56 and 26 hemiplegic patients
(chronic phase > 1 year) by making a comparison with the
contralateral limb which did not receive any injections. The
ultrasound analysis was conducted 1 to 2 months after a single
injection in the gastrocnemius muscles with commonly-used doses.
Tok et al. excluded patients who beneﬁted from injections within the
previous year [30]. They reported a decrease in muscle thickness and
for the pennation angle as well as an increase in the muscle fascicle
length [30]. Picelli et al. [29] did not report any changes in muscle
echo intensity after injection. They considered that the efﬁcacy of the
injections was diminished in spastic muscles with increased echo
intensity, evidencing muscular degeneration (Heckmatt III-IV scale).
Boyaci et al. [28] in 16 children with cerebral palsy and Kwon et al.
[15] on one single patient, reported increased medial gastrocnemius
thickness 4 weeks after one single injection (in the range of 2 mm).
However, the injection was performed with lower doses than those
usually used and children had previously beneﬁted from an
intensive rehabilitation program including muscle strengthening.
Magnetic Resonance Imaging (MRI) helps reﬁne the level of
muscle atrophy by quantifying muscle volume and analyzing the
signal of fatty tissue involution. According to Schroeder et al. [26],
Van Campenhout et al. [33], and William et al. [34], after a single
injection of botulinum toxin, muscle atrophy sets in (from 4 to
30%). This atrophy lingers from 6 months to 1 year after an
injection in healthy subjects [26], and in diplegic children [33]. For
Van Campenhout et al., the proximal injection of the psoas fascia of
the iliopsoas muscle induces a 20% reduction in muscle volume at
2 months [33] whereas, a distal injection was not correlated to
atrophy.
3.3.3. Changes in the passive mechanical properties of the muscle
We looked for changes in the passive stiffness of the muscular
system (ratio between the variation in muscle length and the
stretching force). It is most often quantiﬁed based on Young’s
modulus (E) determined by the ratio stress/strain (E = s/e, in MPa
with s = stress in MPa and e: L – L0/L0 = strain).Two studies on animal models reported an in-vitro analysis on a
healthy muscle [25,35]. The analysis was performed at the scale of
the muscle (gastrocnemius, calcaneal tendon, calcaneus) related to
its lever arm: [35], or at the scale of a ﬁber bundle of the anterior
tibialis muscle [25]. Calculation of the elastic modulus was
performed by creating stretching and recording the changes in
the length of the muscle-tendon unit or muscle ﬁbers and passive
strain necessary for displacement. Haubruck et al. [35], showed
that 8 days after an injection there was a signiﬁcant reduction of
stiffness in the range of 30%. For Thacker et al. [25], one month after
an injection on a single muscle ﬁber, the elastic modulus decreased
by 15% and so did the muscle ﬁber. Furthermore, the passive elastic
modulus of ﬁber bundles doubled after one injection. The variable
difference between a unique muscle ﬁber and ﬁber bundles can be
explained by the accumulation of intermyoﬁbrillar collagen.
Five studies analyzed the viscoelastic properties of spastic
muscles, including 4 studies on children with cerebral palsy after
injection of BoNtA [14,15,28,36,37]. Alhusaini et al. [36] assessed
the stiffness of the triceps surae–calcaneal tendon–talocrural joint
unit, by measuring the passive torque during passive rhythmic
rotation of the ankle at slow speed (608/s). They did not evidence
any signiﬁcant changes in stiffness 6 weeks post injection. The
other studies used elastography imaging [14,15,28,37]. Its princi-
ple resides in measuring the strain induced by the compression of
biological tissues. The Shear Wave Elastography (SWE) technique
implies the production of shear waves through the tissues, thus
generating a strain on the tissue. The elasticity of muscle tissue is
represented by color mapping [14,15,28,37] and quantiﬁed by
measuring either the strain ratio or the elastic modulus. When the
elastic modulus is greater, the muscle becomes stiffer. Four weeks
after an injection in the medial gastrocnemius muscle, there is a
decrease in muscle stiffness related to a reduction of spasticity
[15,28,37]. Studies by Boyaci et al. and Park et al. [28,37] associate
the effect of the botulinum toxin injection to an intensive
rehabilitation program (stretching and muscle strengthening
exercises).
The study of muscle stiffness is quite complex. It must be in
accordance with the system of analysis used: muscle ﬁber, muscle,
muscle-tendon unit, muscle-tendon-joint unit, and the evaluation
method. In children with cerebral palsy, a few weeks after an
injection of botulinum toxin, the stiffness of the system: triceps
surae–calcaneal tendon–talocrural joint, measured using the ratio
passive torque/angle joint was not modiﬁed [36]. However, the
stiffness of the medial gastrocnemius muscle, measured via SWE,
had decreased [15,28,37].
4. Discussion
Looking for structural and mechanical changes in the spastic
muscle after injection of botulinum toxin has rarely been reported
in the literature, in humans and animals alike, and the few studies
that did focus on this topic had very different analytic methods.
However, the stakes of such changes are very important: being
aware, on a structural level, of the muscular deterioration induced
by botulinum toxin; deducing the changes in tissue stiffness in
regards to the system of analysis chosen; and implementing in
humans reliable evaluation modalities for both muscle structure
and stiffness.
In fact, on a structural level, we can report that in animals, one
single injection of BoNtA induces muscle atrophy that lingers for at
least one year, with loss of muscle mass. Repeated injections major
this atrophy and increase its duration with a dose-effect and
frequency of the injections [19,24]. The transition of myosin heavy
chains (MHC) towards slower phenotypes [18,21,25], might
change the conditions of the muscle ﬁbers’ dynamic contraction
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proﬁle and are often injected, this decrease in contractile proteins
induces a decrease in the maximum strength, lingering more than
one month post injection, it is proportional to the dose injected
[18,39] and has an impact on the shortening speed of muscle ﬁbers.
In humans, these data cannot be fully extrapolated. Only the study
by Schroeder et al., in healthy lateral gastrocnemius muscles,
unveils classic signs of neurogenic atrophy [26].
Based on a non-invasive exploration via 2D ultrasound, the
measurements of muscle thickness and pennation angle at the
level of the gastrocnemius muscles are reproducible at rest in
healthy subjects, children [40], older adults [31] and in post-stroke
hemiplegic patients [32]. This requires abiding by a standardized
procedure for the location of ultrasound landmark measurements.
However, the articles in this literature review presenting the
architectural consequences on muscles of botulinum toxin
injections did not describe any standardized measurement
procedures [29,30]. The following settings and procedure must
be respected to meet reproducibility and sensitivity criteria: 2D
ultrasound machine with a probe adapted for muscle analysis
(linear probe with a 6-15 Hz frequency); experienced operator
with a solid knowledge of muscle anatomy, including the fascial
organization of muscles to evaluate changes in muscle architecture
via ultrasound; ﬁnally a validated institutional reproducible
procedure of ultrasound anatomical landmarks and measurements
done. Furthermore, it has been reported in 2D ultrasound that
when the muscle has a high signal intensity and a loss of fascicle-
like organization of the muscles ﬁbers, there is a greater fatty
inﬁltration muscle ﬁbrosis [41]. This latter evaluation is strictly
qualitative and depends on a wide inter-individual echogenicity,
especially according to the thickness of the subcutaneous fat
pedicle. The use of MRI in muscle analysis has rarely been reported
in this context of post botulinum toxin injection [26,33,34],
whereas the technique allows an interesting analysis of the
denervated muscle [42].
Muscle atrophy has been evidenced, but its intensity, duration,
reversible nature, or even its compensation by other muscles
remains unknown. According to the study by William et al. [34],
among a population of children with cerebral palsy, the volume of
the non-injected soleus muscle was increased (4%) suggesting a
compensating mechanism within the triceps surae muscle.
Studies on musculoskeletal stiffness after injection of botu-
linum toxin in humans and animals were conducted with very
different protocols, all using variable criteria. Thus, the resulting
data are very heterogeneous and can sometimes seem contradic-
tory. There has not been an assessment of the consequences of
injections on muscle stiffness beyond 6 weeks. However, patients
who beneﬁt from a treatment with botulinum toxin receive
repeated injections several times a year, for a long period of time.
The concept of muscle stiffness is related to its behavior as a
viscoelastic environment. In fact, in the case of the spastic muscle,
stiffness can be reﬁned and assessed according to the analytic
approach. In a clinical approach, it is the limitation of the joint
range of movement when the muscle is subjected to passive
stretching (stretching hyperreﬂexia or tendon-muscle retraction).
In a biomechanical approach, the study refers to a model analyzing
the elastic structures of the muscle-tendon system, such as the
biomechanical muscle model of Hill [43] that takes into account
the contractile element (CE) and two non-linear spring elements,
one in series (SE) and another in parallel (PE). The latter yields
information on viscoelastic properties at rest. In humans, the
evaluation of passive muscle stiffness is possible on a ‘‘relatively’’
isolated muscle using passive movements [44]. The relationship
passive torque/joint angle is based on the measurement of the
force exerted to mobilize the joint under different angles. This
relationship is not a linear one and maximum torque can varydepending on the given joint [45] due to the variable quantity of
conjunctive tissue in the muscle groups. This method remains the
gold standard, it was initially used to measure the consequences of
muscle lengthening by successive plaster casting [46] on muscle
and tendons. Nevertheless, and to our knowledge, the only study
[36] conducted after an injection of botulinum toxin in spastic
muscles, did not ﬁnd any decrease in passive stiffness for the
triceps surae–calcaneus–talocrural joint, 6 weeks after the
injection. However, in animal models, the passive elasticity
module of muscle fascicles increases 1 month post-injection
[25]. No potential correlation with the increased collagen and
structure protein regulating the viscoelastic properties of muscles,
such as the titin protein, was demonstrated. Following a more
mechanical approach, the ‘‘stiffness’’ of muscle tissue, as a
viscoelastic material, depends on the intrinsic muscle structure
and its contractile status at rest. It can be analyzed via elastography
imaging. The use of this non-invasive method, in real time, and
without any involvement of the patient, seems adapted to the
evaluation and follow-up of neuromuscular pathologies, especially
spasticity and its local treatment. The reproducibility of this
technique still needs to be analyzed in pathologic populations
according to a well-determined procedure: experimented opera-
tor, standardized mapping of an echo-anatomical area, technical
condition (control of the exerted pressure).
5. Conclusion
Even though the use of BoNtA is recommended in the literature
[47–49], and its functional beneﬁts have been acknowledged
[50–52], this review of the literature demonstrates that these
injections lead to structural changes in the muscle: lingering
atrophy, with a remodeling of the muscle contractile proteins, which
is probably not completely reversible; and changes in muscle
elasticity. It seems essential, in light of the repeated injections of
BoNtA in one single individual, to conduct further studies on
muscular changes induced by BoNtA injections. Speciﬁcally, it
requires the implementation of validated and non invasive
exploration procedures, at rest and in motion. The 2D ultrasound
imaging, coupled with a validated measurement procedure via
elastography imaging, appears to be the best technique to meet this
requirement. The challenge being to better deﬁne the indications for
injections and associated treatments such as stretching, posture,
lengthening casts, muscle strengthening and in some speciﬁc cases,
surgical management.
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